<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05628857</url>
  </required_header>
  <id_info>
    <org_study_id>RC108-C002</org_study_id>
    <nct_id>NCT05628857</nct_id>
  </id_info>
  <brief_title>A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor</brief_title>
  <official_title>A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of RC108 for Injection in the Treatment of Patients With c-Met-positiveAdvanced Digestive System Malignant Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, open-label, study designed to evaluate the preliminary efficacy, safety and&#xD;
      pharmacokinetics of RC108 in patients with c-Me-positive advanced digestive system&#xD;
      malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this trial is to evaluate the preliminary efficacy, safety and&#xD;
      efficacy of RC108 in patients with c-Me positive advanced gastrointestinal malignancies such&#xD;
      as gastric, colorectal, esophageal, hepatic, pancreatic and bile duct cancers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2022</start_date>
  <completion_date type="Anticipated">October 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>The disease control rate is the proportion of those subjects with complete response, partial response, or stable disease, as defined by Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>DOR is defined as the time from the participant's initial objective response to study drug therapy to disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Time to progression will be measured from the first day of study drug until progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>PFS time is defined as the time from the participant's first dose of RC108 to either the participant's disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Duration from date of sub-study registration (or date of screening/pre-screening registration if patient never enrolls in a sub-study) to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t)</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Maximum observed plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Time to Cmax (Tmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half life</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Terminal elimination half life.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Digestive Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gastric cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>colorectal cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>liver cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>other digestive system malignancies, including esophageal cancer, pancreatic cancer, gallbladder cancer, etc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RC108</intervention_name>
    <description>RC108 is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>cohort 2</arm_group_label>
    <arm_group_label>cohort 3</arm_group_label>
    <arm_group_label>cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary agreement to provide written informed consent.&#xD;
&#xD;
          2. Male or female, aged between 18 to 75 years.&#xD;
&#xD;
          3. Predicted survival for ≥ 12 weeks. Diagnosed with histologically or cytologically&#xD;
             confirmed locally advanced or metastatic Digestive System Malignant Tumor.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.&#xD;
&#xD;
          5. All female subjects will be considered to be of child-bearing potential unless they&#xD;
             are postmenopausal, or have been sterilized surgically. Female subjects of&#xD;
             child-bearing potential must agree to use two forms of highly effective contraception.&#xD;
             Male subjects and their female partner who are of child-bearing potential must agree&#xD;
             to use two forms of highly effective contraception.&#xD;
&#xD;
          6. Willing to adhere to the study visit schedule and the prohibitions and restrictions&#xD;
             specified in this protocol.&#xD;
&#xD;
             Adequate organ function, evidenced by the following laboratory result Participant has&#xD;
             adequate bone marrow, renal, and hepatic function.&#xD;
&#xD;
          7. bone marrow function: Hemoglobin ≥ 9g/dL; Absolute neutrophil count ≥ 1.5×10^9 /L&#xD;
             Platelets ≥ 100×10^9 /L.&#xD;
&#xD;
          8. hepatic function: Total bilirubin ≤ 1.5× ULN; AST and ALT ≤ 2.5×ULN and ≤ 5 x ULN with&#xD;
             hepatic metastasis&#xD;
&#xD;
          9. renal, and hepatic function: Serum creatinine ≤1.5×ULN.&#xD;
&#xD;
         10. Cardiac ejection fraction ≥ 50%. Median QTc &lt; 450 ms.&#xD;
&#xD;
         11. c-Met positive as confirmed by the central laboratory.&#xD;
&#xD;
         12. Measurable lesion according to RECIST 1.1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to the components of RC108-ADC.&#xD;
&#xD;
          2. Toxicity of previous anti-tumor treatment not recovered to CTCAE (v5.0) Grade 0-1&#xD;
             (with exception of Grade 2 alopecia).&#xD;
&#xD;
          3. Uncontrolled pericardial effusion or cardiac tamponade, or pleural or abdominal&#xD;
             effusion with clinical symptoms.&#xD;
&#xD;
          4. History of receiving any anti-cancer drug/biologic treatment within 4 weeks prior to&#xD;
             trial treatment.&#xD;
&#xD;
          5. History of major surgery within 4 weeks of planned start of trial treatment.&#xD;
&#xD;
          6. Has received a live virus vaccine within 4 weeks of planned start of trial treatment.&#xD;
&#xD;
          7. Currently known active infection with HIV or tuberculosis.&#xD;
&#xD;
          8. Diagnosed with HBsAg, HBcAb positive and HBV DNA copy positive, or HCVAb positive.&#xD;
&#xD;
          9. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
         10. History of other malignancy within the previous 5 years, except for appropriately&#xD;
             treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with&#xD;
             a similar curative outcome as those mentioned above.&#xD;
&#xD;
         11. Known central nervous system metastases.&#xD;
&#xD;
         12. Uncontrolled hypertension, diabetes, pulmonary fibrosis, acute lung disease,&#xD;
             Interstitial lung disease, or liver cirrhosis;&#xD;
&#xD;
         13. Pregnancy or lactation.&#xD;
&#xD;
         14. Assessed by the investigator to be unable or unwilling to comply with the requirements&#xD;
             of the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hopspital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>000000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lin shen, PHD</last_name>
      <phone>13911219611</phone>
      <email>linshenpku@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>November 17, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>March 5, 2023</last_update_submitted>
  <last_update_submitted_qc>March 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Digestive Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

